Target intelligence / Profile preview

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 pseudogene 1 (ST6GALNAC2P1)

Target: ST6GALNAC2P1
Molecular classification: Pseudogene, Processed pseudogene

Overview

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 pseudogene 1 (ST6GALNAC2P1) is a pseudogene and does not produce a functional protein product. It is not considered a therapeutic target and has no known biological, enzymatic, or disease roles. This gene is classified as a processed pseudogene and is most commonly referenced by its full name or the abbreviation ST6GALNAC2P1.

Other names: ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 pseudogene 1ST6 GalNAc alpha-2,6-sialyltransferase 2 pseudogene 1ST6GALNAC2P1

Beyond the preview

Go deeper on ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 pseudogene 1 (ST6GALNAC2P1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 pseudogene 1 (ST6GALNAC2P1).

Explore the full profile